You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》重磅藥修美樂上季銷售跌 藥廠AbbVie(ABBV.US)收入仍勝預期
阿思達克 02-03 00:12
藥廠AbbVie(ABBV.US)周五上調今年盈測目標,將全年調整後盈利預測上調至每股11.05美元至11.25美元。不過,受仿製藥競爭日益激烈,AbbVie於2023年第四季經調整每股收益為2.79美元,按年跌22.5%,符合預期。該股周五升少於1%,創52周新高。 由於旗下重磅藥物修美樂(Humira)銷售額下降,AbbVie第四季淨收入跌5.4%至143.01億美元,高於分析師預測的140.2億美元。 因仿製藥競爭,免疫疾病療法Humira收入下降41%至33億美元,而關節炎藥物Skyrizi和Rinvoq銷售額分別增長52%和63%。 AbbVie全年經調整每股盈利11.11美元,按年跌19.3%,全年純利跌6.4%至543.18億美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account